阿立哌唑和利培酮应用在精神分裂症治疗中的临床疗效及不良反应发生率分析
Analysis of clinical efficacy and incidence of adverse reactions of aripiprazole and risperidone in the treatment of schizophrenia
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2022, 49(1) |
| 作者 |
|
| 作者单位 |
新乡医学院第二附属医院早期干预一科 ;
|
| 摘要 |
[摘要]目的：分析精神分裂症患者应用阿立哌唑和利培酮治疗的临床疗效及不良反应发生率。方法：将2019年7月—2020年10月接诊且行利培酮治疗的40例精神分裂症患者作为对照组，将同期接诊且在对照组基础上加用阿立哌唑治疗的40例精神分裂症患者作为观察组，对组间精神症状改善情况、糖脂代谢指标、血清催乳素（PRL）、临床疗效、不良反应发生率展开分析。结果：（1）组间精神症状改善情况、糖脂代谢指标在治疗前无明显差异，P>0.05；治疗8周后，观察组精神症状改善情况、糖脂代谢指标优于对照组，P<0.05；（2）组间血清PRL在治疗前无明显差异，P>0.05；观察组治疗4周（15.66±4.47）ng/mL、6周（15.87±4.27）ng/mL、8周（16.18±4.52）ng/mL时的血清PRL水平低于对照组（20.43±3.43）ng/mL、（33.58±4.13）ng/mL、（51.74±4.66）ng/mL，P<0.05；（3）治疗8周后，观察组2例无效（5.00%），对照组10例无效（25.00%），P<0.05；（4）观察组不良反应发生率（7.50%）与对照组（12.50%）无明显差异，P>0.05。结论：对精神分裂症患者进行阿立哌唑+利培酮治疗，可以增强疗效，尽快缓解精神症状，减轻对PRL、糖脂代谢的影响，安全性高，值得推广。
|
| Abstract |
[Abstract] Objective: To analyze the clinical efficacy and adverse reaction rate of aripiprazole and risperidone in the treatment of schizophrenia. Methods: 40 schizophrenic patients treated with risperidone from July 2019 to October 2020 were selected as the control group, and 40 schizophrenic patients treated with aripiprazole on the basis of the control group were selected as the observation group The incidence of adverse reactions was analyzed. Results: (1) there was no significant difference in the improvement of mental symptoms and the indexes of glucose and lipid metabolism between the two groups before treatment (P > 0.05); After 8 weeks of treatment, the improvement of mental symptoms and the indexes of glucose and lipid metabolism in the observation group were better than those in the control group (P < 0.05)（ 2) There was no significant difference in serum PRL between the two groups before treatment (P > 0.05); The observation group was treated for 4 weeks (15. 66 6 ± 47) ng / ml, 6 weeks (15. 87 4 ± 27) ng / ml, 8 weeks (16. 18 4 ± 52) ng / ml, which was lower than that of the control group (20. 43 4 ± 3.43）ng/mL、（33.58 ± 4.13）ng/mL、（51.74 ± 4.66）ng/mL，P<0.05；（3) After 8 weeks of treatment, 2 cases in the observation group were invalid (5.00%), 10 cases in the control group were invalid (25.00%), P < 0.05. (4) There was no significant difference in the incidence of adverse reactions between the observation group (7.50%) and the control group (12.50%), P>0.05. Conclusion: aripiprazole + risperidone in the treatment of schizophrenia can enhance the curative effect, relieve mental symptoms as soon as possible, reduce the impact on PRL, glucose and lipid metabolism, with high safety, which is worthy of promotion.
|
| 关键词 |
关键词：阿立哌唑；利培酮；精神分裂症；临床疗效；不良反应发生率
|
| KeyWord |
Key words: aripiprazole; Risperidone; Schizophrenia; Clinical effect; Incidence of adverse reactions
|
| 基金项目 |
|
| 页码 |
45-47 |
王清溪*.
阿立哌唑和利培酮应用在精神分裂症治疗中的临床疗效及不良反应发生率分析 [J].
国际精神病学杂志.
2022; 49; (1).
45 - 47.